Available online on 15.07.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
 An International Peer Reviewed Journal

Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial Share Alike 4.0 License which permits unrestricted non commercial use, provided the original work is properly cited

Volume 5, Issue 3, 2020

Open Access

RESEARCH ARTICLE

PREVALENCE AND RISK FACTORS ASSOCIATED WITH VULVOVAGINAL CANDIDIASIS DURING PREGNANCY IN SANA'A, YEMEN

Abdullah AD Al-Rukeimi^{1,2}, Sameera Mohammad Mahdi Al-Hatami³, Dheya A. AL-Danany³, Hassan Abdulwahab Al-Shamahy³, Raghad Abdullah Ali Al Rukeimi⁴

¹Department of Obstetrics and gynecology, Saudi Hajjah Hospital, Hajjah city, Yemen.

²Department of community Medicine, Faculty of Medicine and Health Sciences, Sana'a University, Yemen.

³Department of Medical Microbiology and Clinical Immunology, Faculty of Medicine and Health Sciences, Sana'a University.

⁴Department of Obstetrics and gynecology, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.

ABSTRACT

Background and objective: Women at pregnancy are further susceptible to vaginal colonization and yeast infection. The responsibility of *Candida* colonization in the incidence of preterm birth is correctly established. Knowing regional epidemiology and identifying risk factors of preterm birth are important for management and preventive strategies. The aim of the study was to reveal the prevalence of *Candida* species in vaginal swabs of pregnant women and determine odds ratio of risks for vulvovaginal candidiasis (VVC).

Methods: Pregnant women attendance routine antenatal visits in Al-Olify –family Center in Sana'a city were registered into a cross-sectional study carried out from June 2018 to March 2019. The laboratory works were carried out in the National Center of Public Laboratories (NCPHL). Samples of vaginal swabs were taken from contributors after obtaining oral consent. The classification of the *Candida* species was done by culture on HiCrome *Candida* Differential Agar at 35 °C for 48 h for making of species-specific colors. Data of demographic, clinical and risk factors were collected in a pre-designed questionnaire.

Results: A total of 190 pregnant women are included. The rate of VVC was 51.6%. *Candida albicans* accounted for 39.5% and non-*Candida albicans* accounted for 12.1% of isolates, mainly *C. glabrata* (4.7%), *C. lipolytica* (3.2%), and *C. famata* (2.1%). When VVC risk factors were considered, there were significant risk factors with the age group 20-24 years (61%, odds ratio (OR)=1.8), first trimester of pregnancy (61.1%, OR=1.7), Multipara of parity (61.8%, OR=1.9), low socioeconomic level (60.1%, OR=2.4), and illiteracy (68%, OR=2.2). When clinical symptoms were considered, only 86.2% of affected females had clinical signs of VVC.

Conclusions: There is a high probable rate of VVC is found among pregnant women in Yemen, undiagnosed and unnoticed; and this highlights the need for health authorities to develop strategies for diagnosing VVC, including vaginal swabs for candidiasis as a routine procedure for all pregnant women. This study also revealed a steady increase in time with a non-*C. albicans* species prevalence rate. VVC syndrome management guidelines in Yemen should be revised to include a special protocol for pregnant women.

Keywords: *Candida*, Epidemiology, Pregnancy, Sana'a, Vulvovaginal candidiasis, VVC, Yemen.

Article Info: Received 1 May 2020; Revised 5 June; Accepted 6 July, Available online 15 July 2020

Cite this article-

Al-Rukeimi ADA, Al-Hatami SMM, AL-Danany DA, Al-Shamahy HA, Al Rukeimi RAA. Prevalence and risk factors associated with vulvovaginal candidiasis during pregnancy in Sana'a, Yemen. Universal Journal of Pharmaceutical Research 2020; 5(3):1-5.

DOI: <https://doi.org/10.22270/ujpr.v5i3.407>

Address for Correspondence:

Prof. Hassan A. Al-Shamahy, Faculty of Medicine and Health Sciences, Sana'a University, P.O. Box 775 Sana'a, Yemen, Tel: +967-1-239551, E-mail: shmahe@yemen.net.ye

INTRODUCTION

VVC is produced by overgrowth of *Candida* yeasts, especially *Candida albicans*, which is an essential component of vaginal flora¹. VVC symptoms comprise vaginal discharge, pain, itching and swelling of vulvar. In addition, vulgar erythematosis and edema with obstruction are common results. Typical vaginal secretions in VVC are described as cottage cheese-like

in character². It is possible that 75.0% of women may experience VVC during their lifetime³. Microbiological and epidemiological studies indicate that intrauterine infection accompanies up to 40% of preterm births⁴. The *Candida* colonization role was confirmed in the preterm birth occurrence⁵, as the *Candida* were isolated from amniotic fluid in spontaneous women preterm birth^{5,6}. *Candida* has been found to increase

metalloproteinase 9 production by chorioamniotic membranes⁶. Metalloproteinase nine is a protein that remodels connective tissue and has an essential role in the origin of premature labor and early rupture of membranes⁷. Also, the mother's vulvovaginal candidiasis is a most important risk factor for neonatal *Candida* colonization⁸. There is evidence that eliminating *Candida* species during pregnancy may reduce the risk of spontaneous premature birth⁹. In epidemiology, VVC is the next most common cause of vaginosis worldwide, following a bacterial infection. In non-pregnant women, the risk of VVC is about 20%, but it increases by 30% during pregnancy¹⁰. Usually (90%) of infections due to *Candida albicans* are undistruptive and do not cause any symptoms. However, vaginal or vulvar infection may be linked with symptoms and signs for instance severe itching, pain, pruritis, irritation, bad odor, dyspareunia, and dysuria and burning in urination¹⁰. In the Arabian Peninsula, the epidemic of VVC infection varies in diverse countries, even from regions inside the same country¹¹⁻¹³. Thus, local studies are essential to obtain related epidemiological data and features of *Candida* sensitivity to antifungal drugs with the purpose of help manage and treat patients with *Candida* infection.

Regarding the causative species of VVC, some researchers report an increased rate of non-*Candida albicans* species, particularly *C. glabrata*, *C. krusei* and *C. parapsilosis*¹⁴. Some researchers have also found that the incidence of *C. albicans* infection decreases and other *Candida* types including *C. glabrata*, *C. tropicalis*, *C. kefyr*, *C. parapsilosis*, *C. africana*, *C. famata*, *C. dubliniensis*, *C. guilliermondii* and *C. lusitanae* associated mainly with vulvovaginitis from patients with immunodeficiency or in pregnant women¹⁰. In Yemen, vaginitis is one of the most common conditions for seeking medical care. In the city of Sana'a, vaginal infections have spread in Yemen among 37.6% of women of childbearing age, with VVC associated significantly with less than 25 years of age and use of intrauterine contraceptives¹⁵, also in Hadramaut three hundred and seventy two (39.2%) of the 950 pregnant women suffered from abnormal vaginal discharge and were positive for bacterial vaginosis¹⁶. Pregnant women are more likely to experience vaginal colonization and *Candida* infection. The responsibility of *Candida* colonization in the happening of preterm birth is well established. Knowing local epidemiology and identifying risk factors for preterm birth are important for prevention and management strategies, so the purpose of the current study was to determine the prevalence of *Candida* species in the vaginal swabs of pregnant women and to identify the risk factors associated with VVC.

SUBJECTS AND LABORATORY METHODS

Pregnant women attending routine antenatal visits in Al-Olify –family Center in Sana'a city were enrolled into a cross-sectional study carried out from June 2018 to March 2019. Inclusion criteria for subject selection were healthy individuals with no systemic disease. In addition, pregnant women who currently taking

antifungal, steroids, antibiotics, or immunosuppressive drugs in the past 6 months were excluded. The sample included 190 pregnant mothers. All pregnant women was examined clinically by specialist and vaginal swabs were taken. The vaginal swabs were sent to the National Center of Public Laboratories (NCPHL) where the laboratory works were carried out. Vaginal swabs were sampled from the participants after oral approval. Smears were inoculated in chloramphenicol Sabouraud's glucose agar and incubated at 37°C for 24 to 48 hours under aerobic conditions for performing fungal cultivation¹⁷. *Candida* species were identified by culturing HiCrome differential Agar at 35°C for 48 hours to produce species specific colors. Data of demographic, clinical and risk factors were collected in a pre-designed questionnaire.

Data analysis

The data was statistically analyzed using EPI-Info version 6. The difference in the distribution of *Candida* types among groups was based on a comparison of repeat distributions by chi-square test. The odds ratio associated with VVC risk factors was performed by 2x2 tables to obtain an OR, 95% CI, Chi squared and *p* value by uncorrected static tests where the value of *p*<0.05 was considered significant.

Ethical approval

We obtained written consent in all cases. Approval was obtained from the participants prior to collection of samples. The study proposal was evaluated and approved by the Ethics Committee, Faculty of Medicine and Health Sciences, University of Sana'a.

Table 1: The distribution of pregnant women according to their age.

Age groups	Case n=190 pregnant women	
	No.	%
< 20 years	18	9.5
20 -24 years	72	37.9
25-29 years	58	30.5
30-34 years	28	14.7
≥ 35	14	7.4
Mean age	25.4 years	
S. D	4.9 years	
Mode	25 years	
Median	25 years	
Max	39 years	
Min	17 years	
Total	95 %	

RESULTS

A total of 190 pregnant women were included, ranging in age from 17-37 years, with mean±SD of 25.4±4.9 years, most of the women were in the age group 20 -24 years (37.9%) and 25-29 years (30.5%) (Table 1). The prevalence of VVC was 51.6%. *C. albicans* accounted for 39.5% and non-*Candida albicans* accounted for 12.1% of isolates, mainly *C. glabrata* (4.7%), *C. lipolytica* (3.2%), and *C. famata* (2.1%). When VVC risk factors were considered, there were significant risk factors with the age group 20-24 years (61%, OR=1.8), first trimester of pregnancy (61.1%, OR=1.7), Multipara of parity (61.8%, OR=1.9), low

socioeconomic level (60.4%, $OR=2.4$), and illiteracy (68%, $OR=2.2$). When clinical symptoms were considered, only 86.2% of affected females had clinical signs of VVC. Subgroup prevalence of vulvovaginal candidiasis is presented in Table 2. Younger women, <20 years had a somewhat lower prevalence (33.3%) of vulvovaginal candidiasis, while in the 20-24 years and older group, the prevalence was between 41.3% and 71.4%. The adjusted odds ratio showed that vulvovaginitis was not significantly associated with older age ($p=0.12$). The prevalence of vulvovaginal candidiasis varied with gestational trimester, parity, education and sociodemographic level. Women who are illiterate were more affected than those patients with primary school education and above. Similarly, vulvovaginal candidiasis was higher among low level

of sociodemographic. Also vulvovaginal candidiasis was higher among multipara mothers (61.8%) compared to nulliparous (38.5%) or paucipares (54.4%) study subjects (Table 2). Table 4 shows the prevalence of *Candida* species according to presence of symptoms. The *Candida* was isolated in most pregnant women who had symptoms of *Candida* VV (86.2%), while only 22.3% was isolated in pregnant women who had no symptoms of *Candida* VV. There was a higher rate of isolated *albicans Candida* in women with symptoms (73.6%) compared to 10.7% in women without symptoms. On the other hand, the percentage of non-*Candida albicans* in symptomatic women (11.7%) is almost similar to 12.6% in asymptomatic women.

Table 2: The risk factors of VV Candidiasis among pregnant women in Sana'a city.

Characters	Positive VVC		OR	CI	X ²	p
	n=98					
	No	%				
Age group						
< 20 years n=18	8	33.3	0.7	0.27-1.9	0.4	0.52
20-24years n=72	44	61	1.8	1.0-3.4	4.2	0.04
25-29 years n=58	24	41.3	0.5	0.29-1.0	3.5	0.06
30-34 years n=28	12	42.8	0.66	0.2-1.4	1.0	0.3
> 35 years n=14	10	71.4	2.5	0.7-8	2.3	0.12
Gestational trimester n=190						
First n= 54	33	61.1	1.7	0.9-3.2	2.7	0.09
Second n=78	36	46.2	0.7	0.3-1.2	1.5	0.21
Third n=58	29	50	0.91	0.4-1.6	0.08	0.77
Parity						
Nulliparous (0 birth) n=65	25	38.5	0.4	0.21-0.8	6.8	0.009
Paucipares (1-2 birth) n=57	31	54.4	1.2	0.6-2.1	0.25	0.6
Multipara (>2 birth) n= 68	42	61.8	1.9	1.03-3.5	4.4	0.03
Sociodemographic						
Low n= 111	67	60.4	2.4	1.3 -4.2	8.2	0.004
Intermediate n=79	31	34.4	0.4	0.2-0.76	8.2	0.004
Educational status						
Illiterate n=25	17	68	2.2	1-5.3	3.1	0.07
Primary school n=32	19	59.4	1.5	0.9-3.1	0.9	0.33
Secondary school n=65	35	53.8	1.1	0.6-8	0.2	0.65
University n=68	27	39.7	0.47	0.25-0.8	5.9	0.01
VVC clinical signs						
Yes n=87	75	86.2	21.7	10-46	77	<0.0001
No n= 103	23	22.3	0.04	0.02-0.09	77	<0.0001

OR=Odds ratio, CI= confidence interval, X²=Chi square, $p=p$ value.

DISCUSSION

Information on the prevalence of VVC in Yemen is not known. Unfortunately, VVC is not a reportable disease and diseases are regularly diagnosed by sign and symptoms without supporting laboratory diagnosis. The same as a result, the spectrum of yeasts involved in causing the disease is unknown in Yemen. The prevalence of VVC among pregnant women is also unknown in Yemen, but it is known worldwide that it is the second most common infection in the vaginal vulva part in women with symptoms as it represents about 17% to 42.%¹⁸⁻²⁰. Even though the prevalence of infection in the current study among pregnant women ranging in age from 17-37 years, with mean±SD of 25.4±4.9 years was 51.6%, slightly higher than the reported range,¹⁸⁻²⁰ it was higher than the prevalence

rates reported by Ahmed and others in India among pregnant and non-pregnant women¹⁹ and Olowe *et al.*, in Nigeria among pregnant women²⁰, however lower prevalence was reported by Erylander *et al.*, among sexually active young women and association with orogenital sex²¹. Differences in rates can be explained by identifying differences in the sociodemographic characteristics and immunity status of patients²², treatment of patients with extensive antibiotics, immunosuppressive drugs²³ and hormonal effects²⁴ as several of the factors for differences in prevalence and/or recurrent VVC between studies. Age, level of education, pregnancy stages, parity and socio-demographic status were investigated as potential risk factors for vulvovaginitis in the present study. There was no strong evidence for the association between

level of education, gestational trimester, and prevalence of VVC. Among the sociodemographic characteristics, age appears to be an important factor in the incidence of VVC in general as the rate of VVC was 61% with OR=1.8, 95% CI=1-3.9, $P=0.04$ in the 20- 24 years age group (Table 2). The current result was similar with a preceding study by Sobel et al.,²⁵, they showed that VVC is rare in puberty (the first appearance of menstruation), but its frequency increases with the end of the second decade of life (10-19 years) and reaches its peak in the third (20-29 years) and the fourth decade (30-39 years old).

Table 3: The frequency of different species of Candida isolated from pregnant women.

Micro-organism species	Pregnant women	
	No.	%
<i>Candida</i> spp	98	51.6
<i>Candida albicans</i>	75	39.5
Non- <i>Candida albicans</i> spp	23	12.1
<i>C. glabrata</i>	9	4.7
<i>C. dubliniensis</i>	2	1.1
<i>C. rugosa</i>	1	0.52
<i>C. lipolytica</i>	6	3.2
<i>C. famata</i>	4	2.1

Although in the current study, the odds ratio detected for the 20-24 age group was significant; the association of older age groups and vaginal candidiasis was not statistically significant as far as the adjusted odds ratio was considered (Table 2); this may point toward that the association was affected by other variables. The incidence was more in pregnant women who are illiterate (68%) than in patients with university education (39.7%). Current results were consistent with those of Rathod et al., in India²⁶, but in disagreement to the conclusion of Vadav and Prakash²⁷. Among the six *Candida* species isolated in this study, the isolated rate for *C. albicans* was 39.5% , 9 (4.7%) for *C. glabrata*, 2 (1.1%) for *C. dubliniensis*, 1 (0.52%) for *C. rugosa*, 6 (3.2%) for *C. lipolytica* and for *C. famata* 4 (2.1%) (Table 3). The results of the current study of *C. albicans* as the predominant species were reliable with similar previous studies^{25,28}. Although many studies on the prevalence of different types of *Candida* have led to the general concurrence that *C. albicans* are the most common isolated species in patients with vulvovaginal candidiasis, there has been an increasing trend to recover non-*albicans Candida* species. This is evidenced by the current study in which the isolation rate of non-*albicans Candida* species was 12.1%. By comparison, more recovery rates for non-*albicans Candida* species were reported at 41.4% in India²⁹ 31.7% in Belgium²⁹ and 19.8% in the United States²⁸. Also higher recovery rates of 53.1%, 65.0% and 57.5% of non-*albicans Candida* species have been reported in studies carried out in India¹⁹, Egypt³¹ and Iran³², correspondingly. Variations in the cure rate were observed between types of non-*albicans Candida* species between the current study and many previous studies. The recovery rate is 4.7% for *C. glabrata*,

1.1% for *C. dubliniensis*, 0.52% for *C. rugosa* and 3.2% for *C. lipolytica* and *C. famata* 2.1% similar to what Trama et al.,²⁸. Studies of Sobel et al.,²⁵, Nergessie³³, Sobel et al.,³⁴, they were discovered that *C. glabrata* was the predominant yeast among non-*albicans Candida* species.

Table 4: The prevalence of Candida species according to presence of symptoms.

Micro-organism species	Asymptomatic n=103		Symptomatic n=87	
	No.	%	No.	%
<i>Candida</i> spp	23	22.3	75	86.2
<i>C. albicans</i>	11	10.7	64	73.6
Non- <i>Candida albicans</i>	12	11.7	11	12.6
<i>C. glabrata</i>	6	5.8	3	3.4
<i>C. dubliniensis</i>	2	1.9	0	0
<i>C. rugosa</i>	1	0.97	0	0
<i>C. lipolytica</i>	1	0.97	5	5.7
<i>C. famata</i>	2	1.9	2	2.3
Total	23	22.3	75	86.2

Bauters et al., research³⁰ showed that *C. glabrata* was the most common non-*albicans Candida* species (16.3%), followed by *C. parapsilosis* (8.9%), *C. humicola* (1.6%), *C. krusei* (0.8%), and *C. lusitanae* (0.8%). Hassanvand et al.,³⁵ *C. albicans* proved to be the most common isolated species followed by *C. glabrata*, *C. tropicalis*, and *C. parapsilosis*. The significance of this result can be explained with caution that *C. glabrata* may replace *C. albicans* under selective pressure of fluconazole, leading to inflammatory resistance to current fluconazole-based treatment in Yemen.

CONCLUSION

There is a high probable rate of VVC among pregnant women in Yemen, and this highlights the need for health authorities to develop strategies to diagnose VVC, including vaginal swabs for candidiasis as a routine procedure for all pregnant women. This study also revealed a steady increase in time with a non-*C. albicans* species prevalence rate. The guidelines for managing VVC syndrome in Yemen should be revised to include a special protocol for pregnant women.

ACKNOWLEDGEMENTS

The authors would like to thank the Ministry of Health and Population, Sana'a, Yemen and the National Center for Public Health Laboratories (NCPHL), the Ministry of Health and Population, Sana'a, Yemen for their support and the provision of workplaces and materials.

AUTHOR'S CONTRIBUTION

This research work is part of the National Center for Public Health Laboratory (NCPHL) project. The authors did clinical and laboratory work. The second author (SMMA) and the corresponding author (HAA) supervised the work of the lab, revised and edited the research.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

REFERENCES

1. Van Schalkwyk J, Yudin MH, Infectious Disease Committee. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. *J Obstet Gynaecol Can.* 2015; 37(3):266–74.
2. Paladine HL, Desai UA. Vaginitis: diagnosis and treatment. *Am Fam Physician* 2018; 97(5):321–9.
3. Achkar JM, Fries BC. Candida infections of the genitourinary tract. *Clin Microb Rev* 2010; 23(2):253–73. <https://doi.org/10.1128/CMR.00076-09>
4. Goldenberg RL, Culhane JF, *et al.* Epidemiology and causes of preterm birth. *Lancet* 2008; 371:75–84. [http://dx.doi.org/10.1016/S0140-6736\(08\)60074-4](http://dx.doi.org/10.1016/S0140-6736(08)60074-4)
5. Ali GY, Algohary EH, Rashed KA, *et al.* AA. Prevalence of Candida colonization in preterm newborns and VLBW in neonatal intensive care unit: role of maternal colonization as a risk factor in transmission of disease. *J Matern Fetal Neonatal Med* 2012; 25:789–95. <http://dx.doi.org/10.3109/14767058.2011.622005>
6. Beghini J, Linhares IM, Giraldo PC, *et al.* Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders. *BJOG* 2015; 122:1580–5. <http://dx.doi.org/10.1111/1471-0528.13072>
7. Lal CV, Xu X, Jackson P, *et al.* Ureaplasma infection mediated release of matrix metalloproteinase-9 and PGP - a novel mechanism of preterm rupture of membranes and chorioamnionitis. *Pediatr Res* 2016; 81:75–7. <http://dx.doi.org/10.1038/pr.2016176>
8. Abdallah Y, Kaddu-Mulindwa D, Nankunda J, Musoke PM. Prevalence and immediate outcome of Candida colonized preterm neonates admitted to Special Care Unit of Mulago Hospital, Kampala Uganda. *Afr Health Sci* 2015; 15:197–205. <http://dx.doi.org/10.4314/ahs.v15i1.26>
9. Roberts CL, Morris JM, Rickard KR, *et al.* Protocol for a randomised controlled trial of treatment of asymptomatic Candidiasis for the prevention of preterm birth. *BMC Pregnancy Childbirth* 2011; 11:19. <http://dx.doi.org/10.1186/1471-2393-11-19>
10. Goncalves B, Ferreira C, Alves CT, *et al.* Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. *Crit Rev Microbiol* 2016; 42:905–27. <http://dx.doi.org/10.3109/1040841x.2015.1091805>
11. Alsharifi EA. Epidemiology of vaginal candidiasis among pregnant women attending Tikrit teaching hospital/Iraq. *J Fac Med Baghdad* 2017; 59(4):1–5. <https://doi.org/10.32007/med.1936/jfacmedbagdad.v59i4.10>
12. Altayyar IA, Alsanosi AS, Osman NA. Prevalence of vaginal candidiasis among pregnant women attending different gynecological clinic at South Libya. *European J Exp Biol* 2016; 6(3):25–29.
13. Al-akeel R A, El-Kersh T A, Al-Sheik Y A, AlAhmady Z Z. Prevalence and comparison for detection methods of Candida species in vaginal specimens from pregnant and non pregnant Saudi women. *African J Microbiol Res* 2013; 7(1):56–65. <https://doi.org/10.5897/AJMR12.1979>
14. Paulitsch A, Weger W, *et al.* A 5-year (2000–2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. *Mycoses* 2006; 49:471–5. <http://dx.doi.org/10.1111/j.1439-0507.2006.01284.x>
15. Abdul-Aziz M, Mahdy MAK, Abdul-Ghani R, *et al.* Bacterial vaginosis, vulvovaginal candidiasis and trichomonal vaginitis among reproductive-aged women seeking primary healthcare in Sana'a city, Yemen. *BMC Infect Dis.* 2019; 19(1):879. <http://dx.doi.org/10.1186/s12879-019-4549-3>
16. Wedad M. Al-Haik. Ahmed M Al-Haddad. Bacterial vaginosis among pregnant women in Hadhramout-Yemen. *AUST J* 2017; 16(7):23–33.
17. Cheesbrough M. Medical Laboratory Manual for Tropical countries. Published by Tropical Health Technology Ltd. 2000, England
18. Anderson MR, Klink K, Cohrsen A. Evaluation of vaginal complaints. *JAMA* 2004; 291:1368–79.
19. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. *Eur J Obstet Gynecol Reprod Biol* 2009; 144:68–71. <https://doi.org/10.1016/j.ejogrb.2008.12.020>
20. Olowe OA, Makanjuola OB, *et al.* Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. *Eur J Microbiol Immunol* 2014; 4:193–7. <https://doi.org/10.1556/EUJMI-D-14-00027>
21. Rylander E, Berglund A-L, Krassny C, Petrini B. Vulvovaginal candida in a young sexually active population: prevalence and association with orogenital sex and frequent pain at intercourse. *Sex Transm Infect* 2004; 80:54–7. <https://doi.org/10.1136/sti.2003.004192>
22. Sobel JD. Candida vulvovaginitis. *Clin Obstet Gynecol* 1993; 36:153.
23. Xu J, Schwartz K, *et al.* Effect of antibiotics on vulvovaginal candidiasis: a Metro Net study. *J Am Board Fam Med* 2008; 21:261–8. <https://doi.org/10.3122/jabfm.2008.04.070169>
24. Spinillo A, Capuzzo E, Nicola S, *et al.* The impact of oral contraception on vulvovaginal candidiasis. *Contraception* 1995; 51:293–7. [https://doi.org/10.1016/0010-7824\(95\)00079-P](https://doi.org/10.1016/0010-7824(95)00079-P)
25. Sobe JD, Faro S, Force RW, *et al.* Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obst Gynecol* 1998; 178:203–11. [https://doi.org/10.1016/s0002-9378\(98\)80001-x](https://doi.org/10.1016/s0002-9378(98)80001-x)
26. Rathod SD, Klausner JD, Krupp K *et al.* Epidemiologic Features of Vulvovaginal Candidiasis among Reproductive-Age Women in India. *Infect Dis Obstet Gynecol* 2012; 2012:859071–8. <https://doi.org/10.1155/2012/859071>
27. Yadav K, Prakash S. Prevalence of vulvovaginal candidiasis in pregnancy. *Glob J Med Sci* 2016; 4:108–16.
28. Ttram JP, Adelson ME, Raphaelli I, *et al.* Detection of Candida species in vaginal samples in a clinical laboratory setting. *Infect Dis Obstet Gynecol* 2005; 13(2):63–7. <https://doi.org/10.1080/10647440400025629>
29. Bitew A and Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. *BMC Women's Health* 2018; 18(94): 1–10. <https://doi.org/10.1186/s12905-018-0607-z>
30. Bauters TGM, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. *Am J Obstet Gynecol* 2002; 187:569–74. <https://doi.org/10.1067/mob.2002.125897>
31. Haleim MMA, El-Feky EAM, Sayed A, *et al.* Prevalence of non albicans species associated with vulvovaginal candidiasis in Egyptian women. *Int J Adv Int Health Sci* 2015; 12:304–13.
32. Hedayati MT, Taheri Z, Galinimorhadam T, *et al.* Isolation of different species of candida in patients with vulvovaginal candidiasis from Sari, Iran. *Jundishapur J Microbiol* 2015; 8:e15992. [https://doi.org/10.5812/jjm.8\(4\)2015.15992](https://doi.org/10.5812/jjm.8(4)2015.15992)
33. Nyirjesy P, Seeney SM, Grody MHT, *et al.* Chronic fungal vaginitis: the value of cultures. *Am J Obstet Gynecol* 1995; 173:820–3. [https://doi.org/10.1016/0002-9378\(95\)90347-X](https://doi.org/10.1016/0002-9378(95)90347-X)
34. Sobel JD, Wiesenfeld HC, Martens M, *et al.* Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med* 2004; 351:876–83. <https://doi.org/10.1056/NEJMoa033114>
35. Hasanvand S, Qomi HA, Kord M, Didehdar M. Molecular epidemiology and *in vitro* antifungal susceptibility of Candida isolates from women with vulvovaginal candidiasis in northern cities of Khuzestan Province. *Iran Jundishapur J Microbiol* 2017; 10(8):12804. <https://doi.org/10.5812/jjm.12804>